[go: up one dir, main page]

PE20091899A1 - Uso de un regimen con virus para el tratamiento de enfermedades - Google Patents

Uso de un regimen con virus para el tratamiento de enfermedades

Info

Publication number
PE20091899A1
PE20091899A1 PE2009000642A PE2009000642A PE20091899A1 PE 20091899 A1 PE20091899 A1 PE 20091899A1 PE 2009000642 A PE2009000642 A PE 2009000642A PE 2009000642 A PE2009000642 A PE 2009000642A PE 20091899 A1 PE20091899 A1 PE 20091899A1
Authority
PE
Peru
Prior art keywords
regime
virus
treatment
diseases
functionality
Prior art date
Application number
PE2009000642A
Other languages
English (en)
Inventor
Werner Krause
Original Assignee
Bayer Schering Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Schering Pharma Ag filed Critical Bayer Schering Pharma Ag
Publication of PE20091899A1 publication Critical patent/PE20091899A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/765—Reovirus; Rotavirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/768—Oncolytic viruses not provided for in groups A61K35/761 - A61K35/766
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011—Details
    • C12N2720/12011—Reoviridae
    • C12N2720/12032—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011—Details
    • C12N2720/12011—Reoviridae
    • C12N2720/12071—Demonstrated in vivo effect
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18111—Avulavirus, e.g. Newcastle disease virus
    • C12N2760/18132—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18111—Avulavirus, e.g. Newcastle disease virus
    • C12N2760/18171—Demonstrated in vivo effect

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

SE REFIERE AL USO DE UN REGIMEN CON VIRUS ONCOLITICOS EN LA PRODUCCION DE UN MEDICAMENTO QUE SE APLICA DESPUES DE INTERRUMPIR O MODIFICAR TEMPORALMENTE LA FUNCIONALIDAD DEL SISTEMA INMUNE YA SEA EN FORMA LOCAL O EN TODO EL ORGANISMO, CON UN SUPRESOR O MODIFICADOR DE LINFOCITOS T TAL COMO UN ANTICUERPO MONOCLONAL DIRIGIDO CONTRA CD3, CD4, MUROMONAB-CD3, ALEMTUZUMAB, ENTRE OTROS, QUE REDUCE EL NUMERO Y LA FUNCIONALIDAD DE DICHOS LINFOCITOS. DICHO MEDICAMENTO PRODUCIDO CON EL REGIMEN DE VIRUS ES UTIL EN EL TRATAMIENTO DE CANCER
PE2009000642A 2008-05-09 2009-05-08 Uso de un regimen con virus para el tratamiento de enfermedades PE20091899A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP08075487 2008-05-09
US5278008P 2008-05-13 2008-05-13

Publications (1)

Publication Number Publication Date
PE20091899A1 true PE20091899A1 (es) 2010-01-21

Family

ID=41265068

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2009000642A PE20091899A1 (es) 2008-05-09 2009-05-08 Uso de un regimen con virus para el tratamiento de enfermedades

Country Status (7)

Country Link
US (1) US20090280122A1 (es)
AR (1) AR071755A1 (es)
PA (1) PA8826101A1 (es)
PE (1) PE20091899A1 (es)
TW (1) TW201004644A (es)
UY (1) UY31819A (es)
WO (1) WO2009135614A2 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012071276A1 (en) * 2010-11-23 2012-05-31 Xiaoliu Zhang Oncolytic virus as an inducer for innate antitumor immunity
BR112018073238A2 (pt) * 2016-05-11 2019-02-19 Ohio State Innovation Foundation vírus oncolíticos compreendendo esrage e métodos de tratamento de câncer

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6565831B1 (en) * 1999-02-24 2003-05-20 Oncolytics Biotech Inc. Methods for preventing reovirus recognition for the treatment of cellular proliferative disorders
WO2001035970A1 (en) * 1999-11-12 2001-05-25 Oncolytics Biotech Inc. Viruses for the treatment of cellular proliferative disorders
WO2003005964A2 (en) * 2001-07-11 2003-01-23 University Of Miami Recombinant vsv for the treatment of tumor cells
MX2008002743A (es) * 2005-08-31 2008-03-26 Oncolytics Biotech Inc Potenciacion in vivo del reconocimiento de neoplasmas por el sistema inmunitario posterior a viroterapia oncolitica o vector para terapia genica.
CA2640286C (en) * 2006-02-13 2018-01-02 Oncolytics Biotech Inc. Use of local immune suppression to enhance oncolytic viral therapy
CA2658584A1 (en) * 2006-07-27 2008-01-31 Ottawa Health Research Institute Staged immune-response modulation in oncolytic therapy
AU2008316276A1 (en) * 2007-10-22 2009-04-30 Oncolytics Biotech Inc. Treatment regime for proliferative disorders

Also Published As

Publication number Publication date
PA8826101A1 (es) 2009-12-16
WO2009135614A2 (en) 2009-11-12
WO2009135614A3 (en) 2010-08-26
AR071755A1 (es) 2010-07-14
TW201004644A (en) 2010-02-01
US20090280122A1 (en) 2009-11-12
UY31819A (es) 2010-01-05

Similar Documents

Publication Publication Date Title
PE20171103A1 (es) Anticuerpos heterodimericos que se unen a cd3 y cd38
MX367241B (es) Uso de anticuerpos contra claudina 18.2 en una terapia de combinación para el tratamiento de cáncer.
AR082149A1 (es) Anticuerpos contra el virus sincicial respiratorio (rsv) humano y metodos para su uso
BR112019012354A2 (pt) anticorpos apenas de cadeia pesada anti-bcma
MX352338B (es) Anticuerpos neutralizantes del virus de la influenza a y usos de estos.
AR090973A1 (es) Anticuerpos utiles para el diagnostico del cancer
MX2016012124A (es) Anticuerpos contra glicopeptidos inmunogenicos, composicion que los comprende y usos de estos.
CL2019000270A1 (es) Composición de cannabis.
MX362456B (es) Anticuerpos y vacunas para utilizarse en el tratamiento de canceres por ror1 y para inhibir la metastasis.
WO2010141093A3 (en) Co-signaling methods for treating cancers
PE20161389A1 (es) Anticuerpos anti-cd38 para el tratamiento de la leucemia linfoblastica aguda
MX2017001815A (es) Celulas hospederas modificadas y oligosacaridos hibridos para su uso en produccion de bioconjugados.
PE20141906A1 (es) Esketamina para el tratamiento de la depresion refractaria al tratamiento o resistente al tratamiento
CO6640238A2 (es) Preparaciones de anticuerpos
ECSP13013060A (es) Composiciones de nucleasa terapéuticas y métodos
ECSP15007345A (es) Métodos para el tratamiento de infecciones de hepatitis b y hepatitis d
MX2019001814A (es) Tratamiento y remision virologica sostenida de infeccion de vih mediante anticuerpos a cd4 en pacientes estabilizados con haart.
PE20130387A1 (es) Composicion farmaceutica y combinacion y metodos para tratar las enfermedades o las condiciones asociadas con la enfermedad o condicion respiratoria
MX2017012867A (es) Composiciones terapeuticas y metodos de uso para tratar el cancer.
MX2018008078A (es) Tecnologia de sinergismo anticuerpo-farmaco para el tratamiento de enfermedades.
MX2020004063A (es) Sistemas y metodos para producir celulas b modificadas geneticamente para expresar anticuerpos seleccionados.
AR086346A1 (es) Proceso para producir un material inorganico particulado
AR086647A1 (es) Metodos para tratar el mesotelioma con un compuesto inhibidor de la pi3k
AR104361A1 (es) Terapia de combinación de anticuerpo que se une a angiopoyetina 2 con anticuerpo que se une al ligando 1 de muerte programada
EA201300138A1 (ru) Фармацевтическая композиция и метод ингибирования продукции или усиления элиминации белка p24

Legal Events

Date Code Title Description
FD Application declared void or lapsed